GlassScriptPhysician profile
Robert S Sterling
NPI 1952494429
$4,215.54
in general payments reported to CMS, 2019-2025
27 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $545 · 2021: $1,057 · 2022: $613 · 2023: $597 · 2024: $415 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.69 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,246.29 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Daiichi Sankyo INC. | $979.30 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $295.65 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $229.80 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $190.72 | 2019-2022 | |
| Avion Pharmaceuticals | $165.99 | 2019-2023 | Balcoltra |
| Caldera Medical, INC | $127.42 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.02 | 2019-2024 | |
| Hologic Sales and Service, LLC | $86.98 | 2024 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $80.33 | 2024-2025 | |
| Exeltis, USA INC. | $68.90 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $64.40 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $57.89 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $55.77 | 2023 | |
| Intuitive Surgical, INC. | $55.34 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $53.28 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Medtronic, INC. | $50.88 | 2021-2024 | Ligasure, Truclear |
| Minerva Surgical, INC | $47.74 | 2024 | |
| Merck Sharp & Dohme LLC | $42.89 | 2019-2021 | |
| Boston Scientific Corporation | $36.22 | 2025 | Bulkamid |
| Evofem Biosciences, INC. | $29.54 | 2020-2021 | |
| Roche Diagnostics Corporation | $29.06 | 2019 | |
| Coopersurgical, INC. | $28.65 | 2024 | Endosee |
| Axonics, INC. | $20.47 | 2024 | Bulkamid |
| Kowa Pharmaceuticals America, INC. | $18.38 | 2023 | Seglentis |
| Myovant Sciences INC. | $15.93 | 2021 | |
| Acessa Health INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.